PPARG: Peroxisome proliferator-activated receptor gamma
A drug works by acting on something in the body, usually a protein made by one gene. This is a page for each of those targets: the drugs that hit it and the diseases it is tied to.
Ligand-activated transcription factor that forms obligate heterodimers with the retinoic acid receptor and acts as a key regulator of biological processes, such as adipocyte differentiation, lipid metabolism, glucose homeostasis and beta-oxidation of fatty acids.
- Drugs that act on it: 30
- Approved: 6
- In phases 1 to 3: 24
- Sponsors: 19
Who Is On It, and How Far Along
Every drug ChEMBL records acting on PPARG, by the furthest stage it has reached for any use, coloured by modality.
How to read this
Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.
- Small molecule
- Other
Approved6
Phase 310
Phase 212
Phase 12
Sponsors
Drugs on this target per company: the US application holder, else the industry sponsor leading the most of its trials.
Modalities
Drugs on this target by ChEMBL molecule type.
- Small molecule2790%
- Other310%
The Landscape
Every drug acting on it, furthest along first. The sponsor is the US application holder where there is one, else the industry lead sponsor of most of its registered trials. 22 of 30 act as: Peroxisome proliferator-activated receptor gamma agonist; the rest name their own mechanism.| Pioglitazone | Approved | Takeda Pharmaceuticals USA | Small molecule | Agonist | — | 52 | Boxed warning |
| Mesalamine | Approved | Viatris | Small molecule | Agonist | — | 28 | — |
| Rosiglitazone | Approved | Woodward | Small molecule | Agonist | — | 3 | WithdrawnBoxed warning |
| Balsalazide | Approved | Bausch Health | Small molecule | Agonist | — | 0 | — |
| Olsalazine | Approved | Viatris | Small molecule | Agonist | — | 0 | — |
| Troglitazone | Approved | Sankyo | Small molecule | Agonist | — | 0 | Withdrawn |
| Saroglitazar | Phase 3 | Zydus Therapeutics Inc. | Small molecule | Agonist | — | 5 | — |
| Leriglitazone | Phase 3 | Minoryx Therapeutics, S.L. | Small molecule | Agonist | — | 1 | — |
| Aleglitazar | Phase 3 | Roche | Small molecule | Agonist | — | 0 | — |
| Balaglitazone | Phase 3 | — | Small molecule | Partial agonist | Peroxisome proliferator-activated receptor gamma partial agonist | 0 | — |
| Bardoxolone methyl | Phase 3 | Biogen | Small molecule | Antagonist | Peroxisome proliferator-activated receptor gamma antagonist | 0 | — |
| Imiglitazar | Phase 3 | Takeda Pharmaceuticals USA | Small molecule | Agonist | — | 0 | — |
| MK-0767 | Phase 3 | Merck & Co. (MSD) | Small molecule | Agonist | — | 0 | — |
| Muraglitazar | Phase 3 | Bristol-Myers Squibb | Small molecule | Agonist | — | 0 | — |
| Rivoglitazone | Phase 3 | Daiichi Sankyo | Small molecule | Agonist | — | 0 | — |
| Tesaglitazar | Phase 3 | AstraZeneca Pharmaceuticals | Small molecule | Agonist | — | 0 | — |
| Arhalofenate | Phase 2 | Gilead Sciences | Small molecule | Modulator | Peroxisome proliferator-activated receptor gamma modulator | 0 | — |
| ATX08-001 | Phase 2 | Astellas Pharma | Small molecule | Modulator | Peroxisome proliferator-activated receptor gamma modulator | 0 | — |
| DB959 | Phase 2 | T3D Therapeutics, Inc. | Other | Agonist | — | 0 | — |
| Efatutazone | Phase 2 | Daiichi Sankyo | Small molecule | Agonist | — | 0 | — |
| Etalocib | Phase 2 | Eli Lilly | Small molecule | Agonist | — | 0 | — |
| Farglitazar | Phase 2 | GSK | Small molecule | Agonist | — | 0 | — |
| INT131 | Phase 2 | InteKrin Therapeutics, Inc. | Small molecule | Modulator | Peroxisome proliferator-activated receptor gamma modulator | 0 | — |
| MBX-2044 | Phase 2 | Gilead Sciences | Other | Modulator | Peroxisome proliferator-activated receptor gamma modulator | 0 | — |
| MK-0533 | Phase 2 | Merck & Co. (MSD) | Small molecule | Modulator | Peroxisome proliferator-activated receptor gamma modulator | 0 | — |
| Naveglitazar | Phase 2 | Eli Lilly | Small molecule | Agonist | — | 0 | — |
| Netoglitazone | Phase 2 | — | Small molecule | Modulator | Peroxisome proliferator-activated receptor gamma modulator | 0 | — |
| OMS405 | Phase 2 | — | Small molecule | Agonist | — | 0 | — |
| AVE0847 | Phase 1 | — | Other | Agonist | — | 0 | — |
| CLX-0921 | Phase 1 | — | Small molecule | Agonist | — | 0 | — |
Open Trials
The most recently posted recruiting or ongoing trials naming each drug (up to 8 a drug), 24 in all, from ClinicalTrials.gov.Diseases Most Associated With It
Open Targets association score, 0 to 1; all associations- Type 2 diabetes mellitus
- 0.86
- PPARG-related familial partial lipodystrophy
- 0.82
- Morbid obesity
- 0.61
- Abnormality of the skeletal system
- 0.58
- Obesity disorder
- 0.57
- Coronary artery disorder
- 0.57
- Colon carcinoma
- 0.52
- Inherited obesity
- 0.51
- Inherited lipid metabolism disorder
- 0.51
- Proctitis
- 0.50
Genes and Related Targets
Complexes and families that share a gene with this target- Genes
- PPARG
Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL235, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-18. Gene name, function (UniProt P37231, CC BY 4.0) and disease associations are from Open Targets (CC0). ChEMBL and Open Targets